Mineralys Therapeutics, Inc. (MLYS) insider trading

Insider

Date

Role

Action

Shares

Price

Amount

Ra Capital Management, L.p.

30 Mar 2026

Director

Buy indirect

58,300

$24.16

$1.41M

Ra Capital Management, L.p.

27 Mar 2026

Director

Buy indirect

310,700

$23.67

$7.35M

Ra Capital Management, L.p.

4 Sep 2025

Director

Buy indirect

1,176,470

$25.50

$30.00M

Srinivas Akkaraju

4 Sep 2025

Director

Buy indirect

588,235

$25.50

$15.00M

Ra Capital Management, L.p.

13 Mar 2025

Director

Buy indirect

1,296,296

$13.50

$17.50M

Srinivas Akkaraju

13 Mar 2025

Director

Buy indirect

600,000

$13.50

$8.10M

Samsara BioCapital GP, LLC

13 Mar 2025

10% owner

Buy indirect

600,000

$13.50

$8.10M

Brian Taylor Slingsby

13 Mar 2025

Director

Buy indirect

259,259

$13.50

$3.50M

Samsara BioCapital GP, LLC

12 Feb 2024

10% owner

Buy indirect

555,555

$13.50

$7.50M

Jon Congleton

22 Nov 2023

Chief Executive Officer

Buy

4,250

$5.97

$25.36K

Jon Congleton

6 Sep 2023

Chief Executive Officer

Buy

2,250

$12.08

$27.18K

Jon Congleton

17 Aug 2023

Chief Executive Officer

Buy

2,250

$12.10

$27.23K

Jon Congleton

11 Aug 2023

Chief Executive Officer

Buy

2,000

$12.89

$25.78K

Brian Taylor Slingsby

14 Feb 2023

Director

Buy indirect

250,000

$16.00

$4.00M

Srinivas Akkaraju

14 Feb 2023

Director

Buy indirect

937,500

$16.00

$15.00M

Adam Scott Levy

14 Feb 2023

CFO, Chief Bus. Off. and Secy.

Buy

6,250

$16.00

$100.00K

Ra Capital Management, L.p.

14 Feb 2023

Director

Buy indirect

1,118,400

$16.00

$17.89M

Ra Capital Management, L.p.

14 Feb 2023

Director

Buy indirect

131,600

$16.00

$2.11M

HBM Healthcare Investments (Cayman) Ltd.

14 Feb 2023

10% owner

Buy

312,500

$16.00

$5.00M

Mineralys Therapeutics, Inc.

What the insiders did Net buying

Individual transactions

What was left out